文献速递头痛与眩晕

Eptinezumab治疗慢性丛集性头痛的长期安全性(CHRONICLE)

Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial.
PubMed 文献 · Lancet Neurol · 2025-01-01

CHRONICLE是一项60周开放标签固定剂量试验,在9国28个头痛中心纳入131例慢性丛集性头痛患者,每12周静脉给予Eptinezumab 400 mg。治疗中出现不良事件者106例(81%),无治疗相关严重不良事件及死亡,攻击频率、疼痛严重度和患者报告结局呈持续改善。

要点

  • Eptinezumab 400 mg每12周静脉给药,治疗中出现不良事件106例(81%)。
  • 常见不良事件为COVID-19(29例,22%)、鼻咽炎(24例,18%)、乏力(23例,18%)。
  • 攻击频率、疼痛严重度和患者报告结局呈持续改善,但需随机对照试验确认临床意义。

核心结论

  • Eptinezumab在慢性丛集性头痛患者中总体耐受良好,安全性特征与偏头痛患者既往所见相似。
  • 观察至12个月可见临床疗效,但需随机对照试验或创新设计试验确认这些观察的临床意义。

研究设计与样本

  • CHRONICLE为60周开放标签固定剂量试验,在9国28个专科头痛中心开展。
  • 纳入131例18-75岁符合ICHD-3慢性丛集性头痛诊断的参与者,Eptinezumab 400 mg每12周静脉给药。
  • 主要目标为通过治疗中出现的不良事件评估长期安全性与耐受性。

主要发现

  • 治疗中出现不良事件106例(81%),导致停药4例、输液中断1例。
  • 最常见不良事件为COVID-19(29例,22%)、鼻咽炎(24例,18%)、乏力(23例,18%,最常见于输液首日)。
  • 试验期间无治疗相关严重不良事件及死亡。
  • 攻击频率、疼痛严重度和患者报告结局呈持续改善。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic cluster headache is an uncommon but highly debilitating primary headache disorder characterised by excruciating head pain recurring in daily attacks and without remission periods longer than 3 months. Treatment is challenging due to the few strategies available. Eptinezumab, approved for migraine prevention, is a humanised monoclonal antibody that targets calcitonin gene-related peptide, which has been implicated in the pathophysiology of cluster headaches. The CHRONICLE trial evaluated the long-term safety and efficacy of eptinezumab for the treatment of chronic cluster headache. METHODS: CHRONICLE was a 60-week, open-label, fixed-dose trial conducted in 28 specialist headache centres in nine countries (Denmark, Finland, France, Germany, Italy, Netherlands, Spain, the UK, and the USA). Participants were aged 18-75 years with a diagnosis of chronic cluster headache according to the International Classification of Headache Disorders, 3rd edition. Eptinezumab 400 mg was administered intravenously every 12 weeks. The primary objective was to evaluate the long-term safety and tolerability of eptinezumab by assessing treatment-emergent adverse events. The efficacy of eptinezumab was assessed by attack frequency, pain severity, and patient-reported outcomes. CHRONICLE is registered on ClinicalTrials.gov (NCT05064397) and EudraCT (2020-001968-28) and is completed. FINDINGS: From Sept 17, 2021, to June 29, 2023, 131 participants were enrolled and treated, of whom 108 (82%) completed the trial. The participants were primarily male (n=84 [64%]), with a mean age of 45·2 years (SD 10·8), and a mean time since diagnosis of 7·3 years (5·8). Treatment-emergent adverse events were reported in 106 participants (81%), with few leading to treatment withdrawal (four participants) or infusion interruption (one participant). The three most common treatment-emergent adverse events were COVID-19 (n=29; 22%), nasopharyngitis (n=24; 18%), and fatigue (n=23; 18%, most commonly on the first day of infusion). There were no treatment-related serious adverse events and no deaths during the trial. Consistent improvements in attack frequency, pain severity, and patient-reported outcomes were observed. INTERPRETATION: Eptinezumab was generally well tolerated in participants with chronic cluster headache, with a similar safety profile as previously seen in participants with migraine. Although clinical efficacy over 12 months was observed, randomised controlled trials (when feasible) or trials with an innovative design are needed to confirm the clinical relevance of these observations. FUNDING: H Lundbeck A/S.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Tassorelli C, Jensen RH, Goadsby PJ, et al. Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial. Lancet Neurol. 2025. PMID: 40252664. doi:10.1016/S1474-4422(25)00065-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。